Acorda Therapeutics, Inc.
ACORQ
OTC PK
| 03/31/2024 | 12/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -46.59% | 37.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -46.59% | 37.06% | |||
| Cost of Revenue | -29.45% | 43.82% | |||
| Gross Profit | -50.19% | 35.71% | |||
| SG&A Expenses | 27.76% | -4.09% | |||
| Depreciation & Amortization | -91.63% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.75% | 3.01% | |||
| Operating Income | -1,003.92% | 119.18% | |||
| Income Before Tax | 89.34% | -2,473.37% | |||
| Income Tax Expenses | 100.30% | -3,512.23% | |||
| Earnings from Continuing Operations | 87.42% | -2,350.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 87.42% | -2,350.06% | |||
| EBIT | -1,003.92% | 119.18% | |||
| EBITDA | -232.98% | 4,722.56% | |||
| EPS Basic | 87.42% | -2,350.06% | |||
| Normalized Basic EPS | -190.81% | 52.23% | |||
| EPS Diluted | 87.42% | -2,348.76% | |||
| Normalized Diluted EPS | -190.81% | 52.23% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
